Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026

Core Viewpoint - Atea Pharmaceuticals, Inc. will host a live conference call on March 5, 2026, to report its financial results for Q4 and the full year ended December 31, 2025, along with a business update [1]. Company Overview - Atea Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapies for serious viral infections [3]. - The company utilizes a proprietary nucleos(t)ide prodrug platform to develop novel product candidates targeting single-stranded ribonucleic acid (ssRNA) viruses, which are significant causes of serious viral diseases [3]. - Atea's current Phase 3 program is evaluating bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for the treatment of Hepatitis C Virus (HCV) [3]. - The company plans to advance AT-587, a nucleotide analog, into Phase 1 for the treatment of Hepatitis E Virus (HEV) after completing first-in-human enabling studies [3].